Search

Your search keyword '"Villaudy, Julien"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Villaudy, Julien" Remove constraint Author: "Villaudy, Julien"
48 results on '"Villaudy, Julien"'

Search Results

1. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

3. 770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients

4. Data from A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia

5. Supplementary Table & Figures from A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia

7. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice

9. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice

10. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses

11. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice

15. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

16. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

18. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

19. Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

20. 721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection

21. Abstract 531: AT1412, a patient-derived antibody in development for the treatment of CD9-positive precursor B-acute lymphoblastic leukemia

22. Abstract 532: A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity

23. Abstract 542: T-cell engager bispecific formats of an AML patient-derived antibody targeting a unique sialylated CD43 epitope induce kill of melanoma cells in vitro and in vivo

25. AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

26. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia

27. HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT)

28. Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice

29. Abstract LB-200: A patient derived antibody targeting the tetraspanin CD9 synergistically inhibits tumor growth with an anti PD1 antibody

30. An antibody derived from a cured AML patient to identify a unique epitope on CD43 (CD43s) as a novel target for acute myeloid leukemia and myelodysplastic syndrome.

31. Abstract A061: Acute myeloid leukemia patients cured after allogeneic hematopoietic stem cell transplantation generate tumor-specific cytotoxic antibodies that kill AML blasts

32. Abstract A026: Tumor-specific glycosylated CD43 is a novel and highly specific target for acute myeloid leukemia and myelodysplastic syndrome

33. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs

35. Développement d’un modèle de souris Rag2-/-γc-/- humanisée pour l’étude de l’infection et de la leucémogénèse associée à HTLV-1

46. HTLV-1 Propels Thymic Human T Cell Development in "Human Immune System" Rag2-/- gamma c-/- Mice.

47. HTLV-1 propels thymic human T cell development in “human immune system” Rag2-/- gamma c-/- Mice

48. [Mice are not Men and yet… how humanized mice inform us about human infectious diseases].

Catalog

Books, media, physical & digital resources